This timeline demonstrates the speed of generic licensing for alimatravir (AMI) compared to lenacapavir (LEN) and cabotegravir (CAB).
- Topics:
- Accelerating Product Innovation
Was this content helpful?
Tell us how we can improve the content.
Was this content helpful?
Thank you for your feedback!